(RSPH) Invesco S&P 500 Equal - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46137V3327 • Health
RSPH: Pharmaceuticals, Biotechnology, Medical, Devices, Equipment, Services
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index is composed of all of the components of the S&P 500® Health Care Index (the 'parent index'). The parent index is designed to measure the performance of common stocks of all companies included in the S&P 500® Index that are classified as members of the health care sector, as defined according to the Global Industry Classification Standard ('GICS®').
Additional Sources for RSPH ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RSPH ETF Overview
| Market Cap in USD | 817m |
| Category | Health |
| TER | 0.40% |
| IPO / Inception | 2006-11-01 |
RSPH ETF Ratings
| Growth 5y | 45.1% |
| Fundamental | - |
| Dividend | 56.9% |
| Rel. Strength Industry | -88.4 |
| Analysts | - |
| Fair Price Momentum | 29.18 USD |
| Fair Price DCF | - |
RSPH Dividends
| Dividend Yield 12m | 0.68% |
| Yield on Cost 5y | 0.97% |
| Annual Growth 5y | 9.63% |
| Payout Consistency | 95.9% |
RSPH Growth Ratios
| Growth Correlation 3m | -64.8% |
| Growth Correlation 12m | 10% |
| Growth Correlation 5y | 72.6% |
| CAGR 5y | 7.32% |
| CAGR/Mean DD 5y | 1.12 |
| Sharpe Ratio 12m | -0.02 |
| Alpha | -20.35 |
| Beta | 0.87 |
| Volatility | 13.39% |
| Current Volume | 173.7k |
| Average Volume 20d | 153.4k |
What is the price of RSPH stocks?
As of January 23, 2025, the stock is trading at USD 30.78 with a total of 173,700 shares traded.
Over the past week, the price has changed by +2.94%, over one month by +4.41%, over three months by -0.90% and over the past year by +3.13%.
As of January 23, 2025, the stock is trading at USD 30.78 with a total of 173,700 shares traded.
Over the past week, the price has changed by +2.94%, over one month by +4.41%, over three months by -0.90% and over the past year by +3.13%.
Is Invesco S&P 500 Equal a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Invesco S&P 500 Equal (NYSE ARCA:RSPH) is currently (January 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 45.07 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RSPH as of January 2025 is 29.18. This means that RSPH is currently overvalued and has a potential downside of -5.2%.
Partly, yes. Based on ValueRay Analyses, Invesco S&P 500 Equal (NYSE ARCA:RSPH) is currently (January 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 45.07 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RSPH as of January 2025 is 29.18. This means that RSPH is currently overvalued and has a potential downside of -5.2%.
Is RSPH a buy, sell or hold?
Invesco S&P 500 Equal has no consensus analysts rating.
Invesco S&P 500 Equal has no consensus analysts rating.
What are the forecast for RSPH stock price target?
According to ValueRays Forecast Model, RSPH Invesco S&P 500 Equal will be worth about 32.3 in January 2026. The stock is currently trading at 30.78. This means that the stock has a potential upside of +4.97%.
According to ValueRays Forecast Model, RSPH Invesco S&P 500 Equal will be worth about 32.3 in January 2026. The stock is currently trading at 30.78. This means that the stock has a potential upside of +4.97%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 32.3 | 5% |